02.03.22
FY Revenues: 62.8 billion CHF (+8%)
FY Earnings: 14.9 billion CHF (-1%)
Comments: Pharmaceuticals Division sales increased 1% to 45.0 billion CHF with continued strong sales for newly launched medicines helping to offset impact of biosimilars. Actemra/RoActemra sales were CHF 3.6 billion, +27%. Avastin sales were CHF 3.1 billion, -37%. Herceptin sales were CHF 2.7 billion, -28%. MabThera/Rituxan sales were CHF 2.6 billion, -38%. Xolair sales were CHF 1.9 billion, +5%, (U.S. only). Newer products: Ocrevus sales CHF 5.1 billion, +19%; Perjeta sales CHF 4.0 billion, +4%; Tecentriq sales CHF 3.3 billion, +24%; Hemlibra sales CHF 3.0 billion, +41%; Kadcyla sales CHF 2.0 billion, +16%; Ronapreve sales CHF 1.6 billion; Alecensa sales CHF 1.4 billion; and Esbriet sales CHF 1.0 billion, -5%. Diagnostics Division sales grew 29% with continued high demand for COVID-19 tests.
Major approvals for in the last quarter include Susvimo and Vabysmo in the U.S. for age-related blindness; Gavreto in Europe for specific type of advanced lung cancer; Actemra/RoActemra for severe COVID-19); Ronapreve for non-hospitalized COVID-19 patients and prophylaxis. In November, Ronapreve was approved in Europe to treat non-hospitalized COVID-19 patients and for prophylaxis of the disease. Data showed that the antibody combination reduces the risk of hospitalization in certain patients with mild to moderate disease and the risk of symptomatic COVID-19 infections in people exposed to the virus. While analyses have shown that Ronapreve does not retain neutralizing activity against the Omicron variant, Ronapreve retains its activity against all other main variants of concern, including Delta.